trending Market Intelligence /marketintelligence/en/news-insights/trending/IQaRHkWxT8Q_aV5-dujWgQ2 content esgSubNav
In This List

Antares Pharma adds Cerecor CEO to board

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Antares Pharma adds Cerecor CEO to board

Antares Pharma Inc. said it appointed Cerecor Inc. Peter Greenleaf to its board.

Greenleaf also serves as chairman of BioDelivery Sciences International Inc.'s board, and is a director of Eyetech Pharmaceuticals. His previous roles include chairman and CEO of Sucampo Pharmaceuticals Inc., now owned by Mallinckrodt Public Ltd. Co., and president of MedImmune LLC and MedImmune Ventures Inc., the biologics arm and venture capital arm, respectively, of AstraZeneca PLC.

Ewing, N.J.-based Antares Pharma is a specialty pharmaceutical company that develops and sells self-administered parenteral pharmaceutical products and technologies worldwide.